Editor’s Note: Cross-posted from the EPA Pesticide Registration and ESA Compliance.
Mr. Bruce Levinson, Senior Vice President—Regulatory Intervention, of CRE will testify at the upcoming FDA meeting on the composition of tobacco leaf. Interested stakeholders should submit relevant information here. [email@example.com]
Nov. 7 Update: Counterfeit Chinese Cigarettes are Flooding Detroit
The public health implications of counterfeit cigarettes, which are extremely high in lead and cadmium, will be discussed in CRE’s testimony.
Nov. 4 Update: Hell’s Angels, NASCAR, and OMB’s Peer Review Bulletin
Murderous motorcycle gangs, the origins of NASCAR, and OMB’s guidance to federal agencies on peer review procedures are only a few of the topics that CRE will discuss on November 16th at the FDA’s risk assessment workshop.
Nov. 2 Update: CRE on Tobacco Leaf Hazard Characterization
CRE’s testimony at the FDA risk assessment workshop will focus on the first question FDA has put to the presenters and panelists, “What toxicological or epidemiological data and methods are available to characterize the hazards associated with constituents that are present in or produced by different types of tobacco products?”
CRE’s testimony will include discussion of how OMB’s Updated Principles for Risk Analysis and OMB’s Final Information Quality Bulletin for Peer Review will govern the FDA’s regulatory risk assessment process.